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Research question
Does early treatment with prednisolone or acyclovir signifi-
cantly improve the symptoms of Bell’s palsy?
Type of study and design
Randomized, blinded, placebo-controlled trial with a 2  2
factorial design to allow separate assessments of prednisolone
(at a dose of 25 mg twice daily), acyclovir (400 mg five times
daily) and a combination of prednisolone and acyclovir was
carried out at the facial palsy clinic in Edinburgh, Scotland.
Relevance to family physicians
Bell’s palsy is an idiopathic, acute peripheral nerve palsy
involving the facial nerve, named after Sir Charles Bell
(1774–1842).1 The crude annualized incidence in Canada in
2002 was 15.2–13.1 per 100,000 population.2 Many have con-
siderable psychological distress and restriction in social activi-
ties due to their facial palsy.3 Most patients recover completely
with or without treatment.4
Clinical trials of the use of steroids and antiviral medica-
tions have had mixed findings and have been inconclusive
because of small sample size. This is the first large randomized
controlled trial of the role of prednisolone and/or acyclovir in
the treatment of Bell’s palsy.
Overview of study methods
The investigators recruited 551 people aged 16 years or older
with a unilateral facial-nerve weakness of no identifiable cause
who presented to primary care (75.3%) or an emergency
department within 72 h of the onset of symptoms. The exclu-
sion criteria were pregnancy, breastfeeding, uncontrolled dia-
betes (glycated haemoglobin, >8%), peptic ulcer disease,
suppurative otitis media, herpes zoster, multiple sclerosis, sys-
temic infection or sarcoidosis. Participants were randomly
allocated to receive prednisolone (at 25 mg twice daily) and
placebo (lactose), acyclovir (400 mg five times daily) and pla-
cebo, prednisolone and acyclovir, or two placebo capsules in
a 2  2 factorial design. Treatment with prednisolone, acyclo-
vir, and both agents or placebos was given for 10 days. Within
3–5 days of randomization, a researcher visited the patients to
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3 months to assess recovery; if recovery was incomplete at this
visit, the visit was repeated at 9 months. Researchers analysed
the clinical records of 15% of patients to validate primary care
and hospital consultation data, toxic effects and coexisting ill-
nesses after the final visit. An independent data and safety
monitoring committee performed a review 14 months after
the recruitment began. The primary composite outcome was
recovery of facial function, as rated on the House-Brackmann
scale. Secondary outcomes were health-related quality of life,
as measured with the Health Utilities Index; facial appearance,
as measured with the Derriford Appearance Scale; and pain, as
measured with the Brief Pain Inventory.
Results
The baseline characteristics of all groups were well balanced.
All patients initiated treatment within 72 h of onset of symp-
toms. The follow-up rate was 90.0%, and 357 patients had
recovered by 3 months and 80 by 9 months; 59 patients had
complications, with a residual facial nerve deficit.
The complete recovery rates differed significantly by group.
In the group that received prednisolone, the absolute risk
reduction was 19.4% (95% confidence interval [CI], 11.7–
27.1) at 3 months and 12.8% (95% CI, 7.2–18.4) at 9 months.
There was no significant difference between the complete
recovery rates in the acyclovir groups, with a trend to a reduc-
tion in the recovery rate at 9 months: 85.4% for patients who
received acyclovir and 90.8% for those on placebo (risk differ-
ence, 5.4%, 95% C1, 11.0 to 0.3, potential ‘number needed
to harm’ = 19). Of the patients receiving the double placebo,
64.7% fully recovered after 3 months and 85.2% after
9 months.
There was no significant difference among the groups in
secondary measures. No major adverse events were reported.
Three deaths were reported, two among patients receiving dou-
ble placebo and one receiving acyclovir, but were deemed to be
unrelated to treatment.
At 3 months, the absolute risk reduction associated with
prednisolone treatment was 19%. Therefore, the number
needed to treat in order to achieve one additional complete
recovery was 6 (95% CI, 4–9). At 9 months, for equivalent
numbers the absolute risk reduction was 12% and the number
needed to treat was 8 (95% CI, 6–14).
Analysis of methodology
This was a well-designed study, with a large sample size and a
good follow-up rate. Most of the patients (75.3%) had been re-
ferred by their family physicians. Analysis was based on the
intention to treat principle. The 2  2 factorial design allowed
all patients to contribute fully to the assessment of separate ef-
fects of prednisolone and acyclovir in a single trial. More than
90% of the randomized patients were included in the analysis.
Comparison with previous studies
This study shows that early use of prednisolone (within 72 h)
contributes to the full recovery of patients with Bell’s palsy
(16 years of age or older). A meta-analysis of four trials com-
prising 179 patients conducted by the Cochrane Collaboration
did not show a significant benefit of steroid therapy in early
treatment of Bell’s palsy.5 Another systematic review by the
Cochrane Collaboration of three trials showed no significant
benefit of acyclovir or valacyclovir.6 Neither review had en-
ough power to detect an effect of either treatment in the man-
agement of Bell’s palsy. A recent randomized controlled trial
showed that valacyclovir and prednisolone combination ther-
apy was more effective than prednisolone alone; however, this
study had several methodological flaws, including the exclu-
sion of 25% of randomized patients from the final analysis
and the fact that the investigators of this trial were aware of
group assignments.7
Bottom line
 The findings of this high-quality study support early use of
prednisolone for the treatment of adults with Bell’s palsy.
 All patients with suspected Bell’s palsy should be assessed
as early as possible so that they can be treated within 72 h.
 In this trial, acyclovir had no benefit in early treatment of
Bell’s palsy. It attenuated the effect of prednisolone and
showed a trend to delaying recovery of patients at 9 months.
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